Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also pr… Read more
Market Cap & Net Worth: Merck & Company Inc (MRK)
Merck & Company Inc (NYSE:MRK) has a market capitalization of $286.50 Billion ($286.50 Billion) as of March 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #47 globally and #36 in its home market, demonstrating a -0.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck & Company Inc's stock price $115.43 by its total outstanding shares 2482022536 (2.48 Billion).
Merck & Company Inc Market Cap History: 2015 to 2026
Merck & Company Inc's market capitalization history from 2015 to 2026. Data shows growth from $96.06 Billion to $286.50 Billion (11.45% CAGR).
Index Memberships
Merck & Company Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Composite Average
DJA
|
$15.45 Trillion | 1.85% | #14 of 65 |
|
DJC: Dow Jones-UBS Commodity Index
DJC
|
$21.30 Trillion | 0.79% | #14 of 65 |
|
Dow Jones Industrial Average
DJI
|
$19.59 Trillion | 1.20% | #14 of 30 |
|
ARCA Pharmaceutical
DRG
|
$2.82 Trillion | 10.13% | #5 of 24 |
|
S&P 500 Index
GSPC
|
$53.10 Trillion | 0.44% | #28 of 503 |
|
S&P 100
OEX
|
$37.25 Trillion | 0.63% | #27 of 101 |
Weight: Merck & Company Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Merck & Company Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Merck & Company Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.02x
Merck & Company Inc's market cap is 4.02 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
14.31x
Merck & Company Inc's market cap is 14.31 times its annual earnings
11.15x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $110.52 Billion | $39.81 Billion | $3.92 Billion | 2.78x | 28.19x |
| 2017 | $108.88 Billion | $40.12 Billion | $2.39 Billion | 2.71x | 45.48x |
| 2018 | $152.38 Billion | $42.29 Billion | $6.22 Billion | 3.60x | 24.50x |
| 2019 | $186.31 Billion | $39.12 Billion | $9.84 Billion | 4.76x | 18.93x |
| 2020 | $172.88 Billion | $41.52 Billion | $7.07 Billion | 4.16x | 24.46x |
| 2021 | $175.92 Billion | $48.70 Billion | $13.05 Billion | 3.61x | 13.48x |
| 2022 | $262.85 Billion | $59.28 Billion | $14.52 Billion | 4.43x | 18.10x |
| 2023 | $265.51 Billion | $60.12 Billion | $365.00 Million | 4.42x | 727.42x |
| 2024 | $246.91 Billion | $64.17 Billion | $17.12 Billion | 3.85x | 14.42x |
| 2025 | $261.26 Billion | $65.01 Billion | $18.25 Billion | 4.02x | 14.31x |
Competitor Companies of MRK by Market Capitalization
Companies near Merck & Company Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Merck & Company Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- Roche Holding AG (OTCQX:RHHBF): Ranked #59 globally with a market cap of $243.19 Billion USD.
- Amgen Inc (NASDAQ:AMGN): Ranked #74 globally with a market cap of $196.91 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #59 | Roche Holding AG | OTCQX:RHHBF | $243.19 Billion | $336.92 |
| #74 | Amgen Inc | NASDAQ:AMGN | $196.91 Billion | $366.25 |
Merck & Company Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Merck & Company Inc's market cap moved from $96.06 Billion to $ 286.50 Billion, with a yearly change of 11.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $286.50 Billion | +9.66% |
| 2025 | $261.26 Billion | +5.81% |
| 2024 | $246.91 Billion | -7.00% |
| 2023 | $265.51 Billion | +1.01% |
| 2022 | $262.85 Billion | +49.42% |
| 2021 | $175.92 Billion | +1.75% |
| 2020 | $172.88 Billion | -7.21% |
| 2019 | $186.31 Billion | +22.27% |
| 2018 | $152.38 Billion | +39.95% |
| 2017 | $108.88 Billion | -1.49% |
| 2016 | $110.52 Billion | +15.05% |
| 2015 | $96.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Merck & Company Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $286.50 Billion USD |
| MoneyControl | $286.50 Billion USD |
| MarketWatch | $286.50 Billion USD |
| marketcap.company | $286.50 Billion USD |
| Reuters | $286.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.